Vnitr Lek 2008, 54(10):950-951

Srdeční amyloidóza - podceňovaná hrozba? - editorial

J. Krejčí
I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC

Received: June 23, 2008; Published: October 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krejčí J. Srdeční amyloidóza - podceňovaná hrozba? - editorial. Vnitr Lek. 2008;54(10):950-951.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Krejčí J. Srdeční amyloidóza. In: Veselka J et al. Hypertrofická kardiomyopatie a příbuzná témata. Praha: Galén 2006: 141-148.
    2. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112: 2047-2060. Go to original source... Go to PubMed...
    3. Kyle RA. Amyloidosis. Circulation 1995; 91: 1269-1271. Go to original source... Go to PubMed...
    4. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the Heart. Arch Intern Med 2006; 166: 1805-1813. Go to original source... Go to PubMed...
    5. Hassan W, AL-Sergani H, Mourad W et al. Amyloid Heart Disease: New frontiers and insights in pathophysiology, diagnosis and management. Tex Heart Inst J 2005; 32: 178-184.
    6. Kuchynka P, Paleček T, Šimek S et al. Izolovaná forma srdeční amyloidózy v podobě počínající infiltrativní kardiomyopatie bez restriktivní fyziologie. Vnitř Lék 2008; 54: 1010-1013. Go to PubMed...
    7. Kothari SS, Ramakrishan S, Bahl VK. Cardiac amyloidosis - an update. Indian Heart J 2004; 56: 197-203.
    8. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: Recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 1999; 74: 490-494. Go to original source...
    9. Khan MF, Falk RH. Amyloidosis. Postgrad Med J 2001; 77: 686-693. Go to original source... Go to PubMed...
    10. Selvanayagam JB, Hawkins PN, Biju P et al. Evaluation and Management of the Cardiac Amyloidosis. J Am Coll Cardiol 2007; 50: 2101-2110. Go to original source... Go to PubMed...
    11. Gregor P. Srdeční amyloidóza. Komentář ke kazuistice autorů Brychta a spol.: Restriktivní kardiomyopatie jako projev primární amyloidózy. Vnitř Lék 2004; 1: 6.
    12. Gertz MA. Diagnosing primary amyloidosis. Mayo Clin Proc 2002; 77: 1278-1279. Go to original source... Go to PubMed...
    13. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednison, and melphalan, prednison and colchicine. N Engl J Med 1997; 336: 102-107. Go to original source... Go to PubMed...
    14. Jaccard A, Moreau P, Leblond V et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-1093. Go to original source... Go to PubMed...
    15. Adam Z, Ščudla V, Tomíška M. Léčba AL-amyloidózy a některých dalších typů amyloidóz. Vnitř Lék 2001; 1: 46-52.
    16. Maurer MS, Raina A, Hesdorffer Ch et al. Cardiac Transplantation Using Extended-Donor Criteria Organs for Systemic Amyloidosis Complicated by Heart Failure. Transplantation 2007; 83: 539-545. Go to original source... Go to PubMed...
    17. Taylor DO, Edwards LB, Boucek J et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Heart Transplant Report - 2007. Heart Lung Transplantation 2007; 26: 769-781. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.